Cargando…
Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol
BACKGROUND: Peripheral atherosclerosis is a common macrovascular complication of diabetes, but the treatment is limited. Chinese herbal medicine is the complementary and alternative therapy to delay the progression of atherosclerosis and reduce blood glucose and lipids. Shen-Qi Xiao-Tan (SQXT) formu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773579/ https://www.ncbi.nlm.nih.gov/pubmed/36550516 http://dx.doi.org/10.1186/s12906-022-03813-9 |
_version_ | 1784855222704668672 |
---|---|
author | Leng, Yulin Fu, Xiaoxu Qian, Lisen Li, Qiqi Gao, Hong Xie, Hongyan Xie, Chunguang |
author_facet | Leng, Yulin Fu, Xiaoxu Qian, Lisen Li, Qiqi Gao, Hong Xie, Hongyan Xie, Chunguang |
author_sort | Leng, Yulin |
collection | PubMed |
description | BACKGROUND: Peripheral atherosclerosis is a common macrovascular complication of diabetes, but the treatment is limited. Chinese herbal medicine is the complementary and alternative therapy to delay the progression of atherosclerosis and reduce blood glucose and lipids. Shen-Qi Xiao-Tan (SQXT) formula is one of the prescriptions commonly used to treat diabetic peripheral atherosclerosis, but there is still a lack of high-quality evidence-based evidence. METHODS: This is a randomized, double-blind, placebo-controlled add-on trial that is expected to enroll 114 diabetic patients with peripheral atherosclerosis. After a 2-week run-in period, participants will been randomly assigned in a 1:1 ratio and receive 12 weeks of usual treatment and SQXT formula (treatment group) or usual treatment and placebo (control group). The primary outcome is the change in carotid intima-media thickness from baseline to endpoint. The secondary outcomes are the structure and function of peripheral arteries, blood glucose and lipids, traditional Chinese medicine syndrome score, and quality of life, and safety and endpoint events are evaluated. To explore the therapeutic mechanism through oxidative stress, inflammation, and advanced glycation end products, and lipidomics will be used to screen for biomarkers for diagnosis and efficacy evaluation. DISCUSSION: The objective of this trial is to evaluate the efficacy, safety and therapeutic mechanism of SQXT formula in the treatment of diabetic peripheral atherosclerosis. It will obtain high-quality evidence-based evidence and promote the treatment of diabetic macroangiopathy and the research and development of new drugs. TRIAL REGISTRATION: This trial is registered on Chinese Clinical Trials.gov with number ChiCTR2100047189 on 10 Jun 2021, and has been approved by the Ethical Review Committee of Hospital of Chengdu University of Traditional Chinese Medicine with number 2020KL-080. |
format | Online Article Text |
id | pubmed-9773579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97735792022-12-23 Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol Leng, Yulin Fu, Xiaoxu Qian, Lisen Li, Qiqi Gao, Hong Xie, Hongyan Xie, Chunguang BMC Complement Med Ther Study Protocol BACKGROUND: Peripheral atherosclerosis is a common macrovascular complication of diabetes, but the treatment is limited. Chinese herbal medicine is the complementary and alternative therapy to delay the progression of atherosclerosis and reduce blood glucose and lipids. Shen-Qi Xiao-Tan (SQXT) formula is one of the prescriptions commonly used to treat diabetic peripheral atherosclerosis, but there is still a lack of high-quality evidence-based evidence. METHODS: This is a randomized, double-blind, placebo-controlled add-on trial that is expected to enroll 114 diabetic patients with peripheral atherosclerosis. After a 2-week run-in period, participants will been randomly assigned in a 1:1 ratio and receive 12 weeks of usual treatment and SQXT formula (treatment group) or usual treatment and placebo (control group). The primary outcome is the change in carotid intima-media thickness from baseline to endpoint. The secondary outcomes are the structure and function of peripheral arteries, blood glucose and lipids, traditional Chinese medicine syndrome score, and quality of life, and safety and endpoint events are evaluated. To explore the therapeutic mechanism through oxidative stress, inflammation, and advanced glycation end products, and lipidomics will be used to screen for biomarkers for diagnosis and efficacy evaluation. DISCUSSION: The objective of this trial is to evaluate the efficacy, safety and therapeutic mechanism of SQXT formula in the treatment of diabetic peripheral atherosclerosis. It will obtain high-quality evidence-based evidence and promote the treatment of diabetic macroangiopathy and the research and development of new drugs. TRIAL REGISTRATION: This trial is registered on Chinese Clinical Trials.gov with number ChiCTR2100047189 on 10 Jun 2021, and has been approved by the Ethical Review Committee of Hospital of Chengdu University of Traditional Chinese Medicine with number 2020KL-080. BioMed Central 2022-12-22 /pmc/articles/PMC9773579/ /pubmed/36550516 http://dx.doi.org/10.1186/s12906-022-03813-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Leng, Yulin Fu, Xiaoxu Qian, Lisen Li, Qiqi Gao, Hong Xie, Hongyan Xie, Chunguang Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol |
title | Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol |
title_full | Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol |
title_fullStr | Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol |
title_full_unstemmed | Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol |
title_short | Efficacy, safety and therapeutic mechanism of Shen-Qi Xiao-Tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol |
title_sort | efficacy, safety and therapeutic mechanism of shen-qi xiao-tan formula in the treatment of peripheral atherosclerosis in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial protocol |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773579/ https://www.ncbi.nlm.nih.gov/pubmed/36550516 http://dx.doi.org/10.1186/s12906-022-03813-9 |
work_keys_str_mv | AT lengyulin efficacysafetyandtherapeuticmechanismofshenqixiaotanformulainthetreatmentofperipheralatherosclerosisinpatientswithtype2diabetesmellitusarandomizeddoubleblindplacebocontrolledtrialprotocol AT fuxiaoxu efficacysafetyandtherapeuticmechanismofshenqixiaotanformulainthetreatmentofperipheralatherosclerosisinpatientswithtype2diabetesmellitusarandomizeddoubleblindplacebocontrolledtrialprotocol AT qianlisen efficacysafetyandtherapeuticmechanismofshenqixiaotanformulainthetreatmentofperipheralatherosclerosisinpatientswithtype2diabetesmellitusarandomizeddoubleblindplacebocontrolledtrialprotocol AT liqiqi efficacysafetyandtherapeuticmechanismofshenqixiaotanformulainthetreatmentofperipheralatherosclerosisinpatientswithtype2diabetesmellitusarandomizeddoubleblindplacebocontrolledtrialprotocol AT gaohong efficacysafetyandtherapeuticmechanismofshenqixiaotanformulainthetreatmentofperipheralatherosclerosisinpatientswithtype2diabetesmellitusarandomizeddoubleblindplacebocontrolledtrialprotocol AT xiehongyan efficacysafetyandtherapeuticmechanismofshenqixiaotanformulainthetreatmentofperipheralatherosclerosisinpatientswithtype2diabetesmellitusarandomizeddoubleblindplacebocontrolledtrialprotocol AT xiechunguang efficacysafetyandtherapeuticmechanismofshenqixiaotanformulainthetreatmentofperipheralatherosclerosisinpatientswithtype2diabetesmellitusarandomizeddoubleblindplacebocontrolledtrialprotocol |